The European Commission today approved the planned sale of Swiss pharmaceuticals firm Actelion to Johnson & Johnson (J&J), subject to conditions.
EU regulators qualified the sale of Europe's biggest.. City A.M.
Jun.26 -- Alex Gorsky, chairman and chief executive officer at Johnson & Johnson, discusses the company’s purchase of Actelion, the state of health care in the United States, and what tax reform.. Source: Bloomberg Politics -
BRUSSELS (Reuters) - EU antitrust regulators approved on Friday Johnson & Johnson's planned purchase of Actelion Pharmaceutical subject to conditions intended to ensure clinical development of insomnia.. Reuters
ZURICH (Reuters) - Swiss biotechnology company Actelion on Thursday presented mixed trial results for its antibiotic hopeful cadazolid, saying it met the main goal of one late-stage study but failed to.. Reuters
ZURICH (Reuters) - The European Medicines Agency on Friday gave its green light for doctors to continue using Actelion's Uptravi, saying a review after five patient deaths in France did not suggest an.. Reuters
ZURICH (Reuters) - Johnson & Johnson declared its $30 billion tender offer for Swiss biotechnology company Actelion successful on Friday, reporting it controlled 77.2 percent of the voting rights after.. Reuters
Global M&A activity so far this year is at its highest level since the financial crisis, expert analysis has revealed.
Some $705bn of deals have been announced since the start of 2017, the first.. City A.M.
Actelion Pharmaceuticals had a very attractive pipeline of new drugs in development. But OPAP, a Greek lottery and sports betting operator, was hit hard by the political crisis in the country. MailOnline
ZURICH (Reuters) - A European Medicines Agency drug safety panel recommended on Friday that Actelion's Uptravi drug may continue to be used in line with current prescription information amid a probe.. Reuters
* J&J - upon termination of transaction agreement, under some circumstances, Actelion may be obligated to pay co a fee - sec filing Source text - http://bit.ly/2jWFeAh Further company coverage: Reuters
ZURICH (Reuters) - The looming foreign takeovers of biotech group Actelion and agrichemicals firm Syngenta look set to trigger the biggest shake-up in the Swiss blue-chip SMI index in years just as.. Reuters